Research Topics
Species | G E KonecnySummaryAffiliation: University of California Country: USA Publications
|
Detail Information
Publications
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancerG E Konecny
Division of Gynecologic Surgery, Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
Br J Cancer 100:89-95. 2009..0197; HER2, P=0.7855). We conclude that assessment of HER2 gene amplification and/or EGFR expression may help to select type II EC patients who could benefit from therapeutic strategies targeting both HER2 and EGFR...
Activity of the Fibroblast Growth Factor Receptor Inhibitors Dovitinib (TKI258) and NVP-BGJ398 in Human Endometrial Cancer CellsGottfried E Konecny
Corresponding Author Gottfried E Konecny, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA 90404
Mol Cancer Ther 12:632-42. 2013..Dovitinib may have antitumor activity in endometrial cancer beyond FGFR2-mutated cases and may permit greater flexibility in patient selection. Mol Cancer Ther; 12(5); 632-42. ©2013 AACR...- Emerging strategies for the dual inhibition of HER2-positive breast cancerGottfried E Konecny
David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90404 2429, USA
Curr Opin Obstet Gynecol 25:55-65. 2013..To review the recently published trials to help us refine and optimize the use of approved HER2-targeted agents (trastuzumab and lapatinib) and highlight future combination strategies for the treatment of HER2-positive breast cancer... - Expression of p16 and retinoblastoma determines response to CDK4/6 inhibition in ovarian cancerGottfried E Konecny
Division of Hematology Oncology, Department of Biomathematics and Biostatistics, David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA
Clin Cancer Res 17:1591-602. 2011..PD-0332991 is a selective inhibitor of the CDK4/6 kinases with the ability to block retinoblastoma (Rb) phosphorylation in the low nanomolar range. Here we investigate the role of CDK4/6 inhibition in human ovarian cancer... - Association between HER2, TOP2A, and response to anthracycline-based preoperative chemotherapy in high-risk primary breast cancerGottfried E Konecny
UCLA Translational Oncology Research Lab, David Geffen School of Medicine, University of California Los Angeles, 2825 Santa Monica Blvd, Suite 200, Santa Monica, CA, 90404 2429, USA
Breast Cancer Res Treat 120:481-9. 2010..However, added benefit of IDD chemotherapy itself was not associated with HER2 or TOP2A status... - Activity of the multikinase inhibitor dasatinib against ovarian cancer cellsG E Konecny
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA 90404 2429, USA
Br J Cancer 101:1699-708. 2009.... 
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancerMark D Pegram
Division of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles 90095-7077, USA
J Natl Cancer Inst 96:739-49. 2004....- Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cellsG E Konecny
Department of Obstetrics and Gynecology, Mayo Clinic, Rochester, MN, USA
Br J Cancer 98:1076-84. 2008..Expression of EGFR, its ligands, HER3, AR, and post-EMT markers warrant further evaluation to help define patients with HER2-nonoverexpressing endometrial cancer most likely to benefit from lapatinib... - Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancerGottfried E Konecny
Division of Hematology-Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, and Jonsson Comprehensive Cancer Center, Los Angeles, CA 90095-7077, USA
J Natl Cancer Inst 96:1141-51. 2004..Furthermore, a taxane-containing regimen such as ET may provide a preferential benefit to patients with HER-2/neu-positive tumors... - Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cellsGottfried E Konecny
Division of Hematology Oncology, Department of Medicine, David Geffen School of Medicine, University of California at Los Angeles, 12 145 Factor Building, 10945 Le Conte Avenue, Los Angeles, CA 90095 1678, USA
Cancer Res 66:1630-9. 2006..These observations provide a clear biological rationale to test lapatinib as a single agent or in combination with trastuzumab in HER-2-overexpressing breast cancer and in patients with clinical resistance to trastuzumab... - Gemcitabine in combination with trastuzumab and/or platinum salts in breast cancer cells with HER2 overexpressionGottfried E Konecny
University of California Los Angeles, David Geffen School of Medicine, Los Angeles, California 90095 1678, USA
Oncology (Williston Park) 18:32-6. 2004..These findings indicate that trastuzumab plus gemcitabine and trastuzumab plus gemcitabine plus cisplatin or carboplatin are rational combinations to evaluate in clinical trials... - Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patientsGottfried E Konecny
Department of Medicine, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California 90095 1678, USA
Clin Cancer Res 10:1706-16. 2004..compare the prognostic significance of VEGF isoforms; and (c). analyze the combined effects of HER-2/neu and VEGF on clinical outcome...